Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

TheraSense buoyed by continuos glucose monitor:

This article was originally published in Clinica

Executive Summary

TheraSense reports that a pivotal trial of its real-time, continuous glucose monitoring system has produced data to support the product's accuracy and efficacy. The results come from the first 30 participants to complete the trial, says the Alameda, California firm, which plans to submit a premarket approval application for the sensor to the US FDA in the second half of 2003. Patients wore the sensors for consecutive three-day periods over 21 days, generating over 3,500 confirmatory capillary blood glucose measurements. These data were compared with capillary finger-stick samples in a Clarke Grid analysis. Some 96.5% of the paired results fell into Clarke Grid regions A and B.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT062651

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel